Concordia Laboratories
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Concordia Laboratories sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Concordia Laboratories: 4 sponsored US clinical trials, none currently recruiting.
Concordia Laboratories sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 1 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Metastasis, with 1 trials.
Upper-quartile sponsor footprint
Concordia Laboratories sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Establishment of a PDT Patient Registry
NCT03589456
Safety of PDT-Photofrin® Prior to Lung Surgery
NCT03344861
Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer
NCT02916745
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
NCT02082522
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 1 |
Therapeutic Areas
How the Concordia Laboratories early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 2 completed (50%).
Phase mix: 1 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Lung Metastasis (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Concordia Laboratories: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Concordia Laboratories sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Concordia Laboratories page
4 registered trials is a research-attention snapshot, not an endorsement of Concordia Laboratories or any single study.
- None of Concordia Laboratories's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lung Metastasis is the condition Concordia Laboratories studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Metastasis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Concordia Laboratories pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.